AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12972483 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardised training only)
Number of subjects: 40
Study 10633535 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (200 to 500 mg/day)
Number of subjects: 45
Study 10633535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 8733067 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 8733067 — intervention group
Group type: EXPERIMENTAL
Intervention: Converting-enzyme inhibitors
Number of subjects: 0
Study 8733067 — intervention group
Group type: COMPARATOR
Intervention: Flosequinan (direct-acting vasodilator)
Number of subjects: 0
Study 8262783 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 76
Study 8262783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 3853573 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential learning through home visits to elderly clients (group A: healthy clients at home, group B: hospitalized clients recuperating at home) over a 3-month period.
Number of subjects: 0
Study 28001465 — intervention group
Group type: EXPERIMENTAL
Intervention: Acreos Adapt AO
Number of subjects: 83
Study 28001465 — intervention group
Group type: COMPARATOR
Intervention: Acrysof SA60AT
Number of subjects: 83
Study 26872709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleave techniques (various)
Number of subjects: 5
Study 26872709 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μm fiber
Number of subjects: 5
Study 26872709 — intervention group
Group type: EXPERIMENTAL
Intervention: 365 μm fiber
Number of subjects: 5
Study 24746649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy at 7.5 FPS
Number of subjects: 363
Study 22698292 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) administered at 2 atm twice a day for 40 treatments as an adjunct to surgery and antibiotics
Number of subjects: 46
Study 22698292 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone (surgery and antibiotics)
Number of subjects: 46
Study 22698292 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO)
Number of subjects: 46
Study 20926017 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentacoll implants (10 × 10 × 0.5 cm, 280 mg collagen sponge plus 200 mg gentamicin sulphate)
Number of subjects: 44
Study 20926017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Gentacoll application)
Number of subjects: 44
Study 18926150 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/d of atorvastatin (high-dose regimen)
Number of subjects: 10001
Study 18926150 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/d of atorvastatin (low-dose regimen)
Number of subjects: 10001
Study 15894964 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/d for 3 weeks)
Number of subjects: 100
Study 15894964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12464207 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine (without vasoconstrictor)
Number of subjects: 93
Study 12464207 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine (with adrenaline 1:80,000)
Number of subjects: 93
Study 12464207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 12464207 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine
Number of subjects: 93
Study 12470125 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention
Number of subjects: 115
Study 12470125 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 115
Study 9713273 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus 5‐FU injection (2-4 min)
Number of subjects: 203
Study 9713273 — intervention group
Group type: COMPARATOR
Intervention: Short-term 5‐FU infusion (10-20 min)
Number of subjects: 203
Study 7994982 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ticlopidine
Number of subjects: 48
Study 7994982 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ticlopidine and 60-150 mg acetylsalicylic acid
Number of subjects: 48
Study 7994982 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cilostazol
Number of subjects: 48
Study 7994982 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (all groups combined)
Number of subjects: 48
Study 2903927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine 2 g/day
Number of subjects: 0
Study 2903927 — intervention group
Group type: COMPARATOR
Intervention: Placebo or Sulfasalazine 0.5 g/day
Number of subjects: 0
Study 2903927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine 1 g/day or 2 g/day
Number of subjects: 0
Study 31722313 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel, a selective non‐competitive AMPA receptor antagonist, administered for 48 weeks
Number of subjects: 0
Study 31722313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28551714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue avoidance training (CAT)
Number of subjects: 120
Study 28551714 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory control training (ICT)
Number of subjects: 120
Study 28551714 — intervention group
Group type: COMPARATOR
Intervention: Sham (control) CAT
Number of subjects: 120
Study 28551714 — intervention group
Group type: COMPARATOR
Intervention: Sham (control) ICT
Number of subjects: 120
Study 25630007 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 28
Study 25630007 — intervention group
Group type: COMPARATOR
Intervention: LASEK
Number of subjects: 28
Study 23312822 — intervention group
Group type: EXPERIMENTAL
Intervention: True anteroposterior (GH AP) view
Number of subjects: 160
Study 23312822 — intervention group
Group type: COMPARATOR
Intervention: Conventional AP view
Number of subjects: 160
Study 21245794 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC‐MPS)
Number of subjects: 396
Study 21245794 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 396
Study 18452622 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation for 5 minutes
Number of subjects: 0
Study 18452622 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation for 15 minutes
Number of subjects: 0
Study 18452622 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation for 30 minutes
Number of subjects: 0
Study 18452622 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 0
Study 16226397 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy with CMF chemotherapy
Number of subjects: 206
Study 16226397 — intervention group
Group type: COMPARATOR
Intervention: Sequential radiotherapy with CMF chemotherapy
Number of subjects: 206
Study 12876090 — intervention group
Group type: COMPARATOR
Intervention: β-carotene (20 mg)
Number of subjects: 25563
Study 12876090 — intervention group
Group type: COMPARATOR
Intervention: α-tocopherol (50 mg)
Number of subjects: 25563
Study 10926587 — intervention group
Group type: EXPERIMENTAL
Intervention: Active inhaler
Number of subjects: 400
Study 10926587 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 400
Study 9594145 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg a day
Number of subjects: 46
Study 9594145 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with perindopril)
Number of subjects: 46
Study 1399429 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy/marine oil
Number of subjects: 0
Study 1399429 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy oil
Number of subjects: 0
Study 1399429 — intervention group
Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 0
Study 1399429 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized group of formula-fed full-term infants
Number of subjects: 0
Study 29449079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 0
Study 29206339 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 46
Study 29206339 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 healthy age-matched subjects)
Number of subjects: 46
Study 26544854 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT)
Number of subjects: 56
Study 26544854 — intervention group
Group type: COMPARATOR
Intervention: Sham radial extracorporeal shock wave therapy (sham rESWT)
Number of subjects: 56
Study 24997050 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi group (D group)
Number of subjects: 150
Study 24997050 — intervention group
Group type: COMPARATOR
Intervention: Swimming group (A group)
Number of subjects: 150
Study 24997050 — intervention group
Group type: COMPARATOR
Intervention: Running group (B group)
Number of subjects: 150
Study 24997050 — intervention group
Group type: COMPARATOR
Intervention: Square dancing group (C group)
Number of subjects: 150
Study 24997050 — intervention group
Group type: COMPARATOR
Intervention: Control group (E group)
Number of subjects: 150
Study 22595151 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible formulation of risperidone (2 mg)
Number of subjects: 22
Study 22595151 — intervention group
Group type: COMPARATOR
Intervention: Branded formulation of risperidone (2 mg)
Number of subjects: 22
Study 22595151 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 22
Study 20622661 — intervention group
Group type: EXPERIMENTAL
Intervention: Early drain removal (POD 3)
Number of subjects: 114
Study 20622661 — intervention group
Group type: COMPARATOR
Intervention: Standard drain removal (POD 5 or beyond)
Number of subjects: 114
Study 16923324 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical antipsychotics
Number of subjects: 30
Study 16923324 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 30
Study 16923324 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30
Study 16923324 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 16923324 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone or Olanzapine
Number of subjects: 30
Study 16142041 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (alone or in combination with oral antidiabetic drugs)
Number of subjects: 2150000
Study 16142041 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 2150000
Study 12084083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK 506) applied 30 min after sodium lauryl sulphate (SLS) irritation
Number of subjects: 0
Study 12084083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK 506) applied 1 x daily for 5 days after the 4-day irritation period
Number of subjects: 0
Study 12084083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK 506) in the UVB erythema model
Number of subjects: 0
Study 10027655 — intervention group
Group type: COMPARATOR
Intervention: 50 microg inhaled salmeterol
Number of subjects: 16
Study 10027655 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral bambuterol
Number of subjects: 16
Study 7595704 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP (doxorubicin)
Number of subjects: 145
Study 7595704 — intervention group
Group type: COMPARATOR
Intervention: CNOP (mitoxantrone)
Number of subjects: 145
Study 2202513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (2 to 4 gm/day)
Number of subjects: 266
Study 2202513 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (4 to 8 gm/day)
Number of subjects: 266
Study 2202513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 266
Study 2202513 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 266
Study 7211276 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanlens 75 high water content lenses
Number of subjects: 0
Study 7211276 — intervention group
Group type: COMPARATOR
Intervention: Bausch & Lomb Soflens U3 low water content lenses
Number of subjects: 0
Study 30685318 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical testing (FIT) with appropriate colonoscopy follow-up
Number of subjects: 8
Study 30685318 — intervention group
Group type: COMPARATOR
Intervention: Usual care clinics
Number of subjects: 8
Study 30685318 — intervention group
Group type: EXPERIMENTAL
Intervention: Lagged data accounting for implementation delay
Number of subjects: 8
Study 28103698 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (5 mg)
Number of subjects: 20
Study 28103698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26580986 — intervention group
Group type: EXPERIMENTAL
Intervention: Black women
Number of subjects: 71
Study 26580986 — intervention group
Group type: COMPARATOR
Intervention: White women
Number of subjects: 71
Study 26580986 — intervention group
Group type: EXPERIMENTAL
Intervention: BPI-interference scores
Number of subjects: 71
Study 25027109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral recombinant salmon calcitonin tablets (once daily for 1 year)
Number of subjects: 129
Study 25027109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 1 year)
Number of subjects: 129
Study 25027109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral recombinant salmon calcitonin tablets (dosing at bedtime or with dinner)
Number of subjects: 129
Study 25027109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral recombinant salmon calcitonin tablets
Number of subjects: 129
Study 21997930 — intervention group
Group type: EXPERIMENTAL
Intervention: K.C. (individual with episodic amnesia)
Number of subjects: 1
Study 21997930 — intervention group
Group type: COMPARATOR
Intervention: Controls (individuals without episodic amnesia)
Number of subjects: 1
Study 19411087 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg/d) for 20 weeks
Number of subjects: 31
Study 19411087 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg/d) for 20 weeks + exercise training (3 d/wk from week 10 to week 20)
Number of subjects: 31
Study 19411087 — intervention group
Group type: COMPARATOR
Intervention: Active control group (physically active hypercholesterolemic subjects)
Number of subjects: 31
Study 17260114 — intervention group
Group type: EXPERIMENTAL
Intervention: SR‐PLA70 screws
Number of subjects: 62
Study 17260114 — intervention group
Group type: COMPARATOR
Intervention: SR‐PLLA screws
Number of subjects: 62
Study 17260114 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SR‐PLA70 and SR‐PLLA screws
Number of subjects: 62
Study 15078262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 268
Study 15078262 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 268
Study 15078262 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus sulfadoxine-pyrimethamine (CQ + SP)
Number of subjects: 268
Study 11430440 — intervention group
Group type: EXPERIMENTAL
Intervention: LIMIRT treatment (840 nm; 3.0 J cm(‐2), pulse frequency 1 kHz)
Number of subjects: 24
Study 11430440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11430440 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 9741502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 59
Study 9741502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 8053582 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg) with high-dose midazolam (group 4)
Number of subjects: 99
Study 8053582 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg) with low-dose midazolam (group 2)
Number of subjects: 99
Study 8053582 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg)
Number of subjects: 99
Study 8053582 — intervention group
Group type: COMPARATOR
Intervention: Control (propofol-placebo, group 1)
Number of subjects: 99
Study 8053582 — intervention group
Group type: COMPARATOR
Intervention: Control (midazolam-placebo, group 3)
Number of subjects: 99
Study 2922831 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression on the extended elbow
Number of subjects: 24
Study 2922831 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression on the flexed elbow
Number of subjects: 24
Study 31510918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB)
Number of subjects: 127
Study 31510918 — intervention group
Group type: COMPARATOR
Intervention: Regular analgesia (Control)
Number of subjects: 127
Study 28161119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg every 4 weeks
Number of subjects: 167
Study 28161119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 26476286 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention including in-person support groups, online support groups, peer navigation, and text message reminders.
Number of subjects: 0
Study 22707232 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem with enamel etching (E)
Number of subjects: 31
Study 22707232 — intervention group
Group type: COMPARATOR
Intervention: RelyX Unicem without enamel etching (NE)
Number of subjects: 31
Study 22707232 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (E)
Number of subjects: 31
Study 22707232 — intervention group
Group type: COMPARATOR
Intervention: RelyX Unicem (NE)
Number of subjects: 31
Study 21951411 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital education plus stroke navigators
Number of subjects: 0
Study 21951411 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19112213 — intervention group
Group type: EXPERIMENTAL
Intervention: Short daily hemodialysis (6 times per week for 1.5 to 2.75 hours)
Number of subjects: 400
Study 19112213 — intervention group
Group type: EXPERIMENTAL
Intervention: Long nocturnal hemodialysis (6 times per week for 6 to 8 hours)
Number of subjects: 400
Study 19112213 — intervention group
Group type: COMPARATOR
Intervention: Short daily hemodialysis
Number of subjects: 400
Study 19112213 — intervention group
Group type: COMPARATOR
Intervention: Long nocturnal hemodialysis
Number of subjects: 400
Study 19112213 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-center hemodialysis
Number of subjects: 400
Study 19112213 — intervention group
Group type: COMPARATOR
Intervention: Conventional home hemodialysis
Number of subjects: 400
Study 17538472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic Compression Device 1 (PCD1)
Number of subjects: 65
Study 17538472 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic Compression Device 2 (PCD2)
Number of subjects: 65
Study 16267077 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care facility
Number of subjects: 320
Study 16267077 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 320
Study 11925995 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT (immunochromatographic card test)
Number of subjects: 242
Study 11925995 — intervention group
Group type: COMPARATOR
Intervention: TBF (thick blood film)
Number of subjects: 242
Study 11925995 — intervention group
Group type: COMPARATOR
Intervention: NMF (Nuclepore membrane filtration)
Number of subjects: 242
Study 9793661 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous and peritoneal bupivacaine (1.5 mg.kg‐1 bupivacaine 0.5%)
Number of subjects: 60
Study 9793661 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous bupivacaine (1.5 mg.kg‐1 bupivacaine 0.5%)
Number of subjects: 60
Study 7697953 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (5, 10, and 20 mg)
Number of subjects: 0
Study 7697953 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (20 mg)
Number of subjects: 0
Study 7697953 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (doses lower than 20 mg)
Number of subjects: 0
Study 7697953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (50, 100, and 200 mg)
Number of subjects: 0
Study 7697953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (doses unspecified)
Number of subjects: 0
Study 7697953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2515136 — intervention group
Group type: EXPERIMENTAL
Intervention: bepridil (100-400 mg/d)
Number of subjects: 191
Study 2515136 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol (60-240 mg/d)
Number of subjects: 191
Study 2515136 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 191
Study 2515136 — intervention group
Group type: EXPERIMENTAL
Intervention: bepridil vs propranolol
Number of subjects: 191
Study 852404 — intervention group
Group type: EXPERIMENTAL
Intervention: BM 15.075 at 450 mg
Number of subjects: 15
Study 852404 — intervention group
Group type: EXPERIMENTAL
Intervention: BM 15.075 at 600 mg
Number of subjects: 15
Study 852404 — intervention group
Group type: EXPERIMENTAL
Intervention: BM 15.075
Number of subjects: 15
Study 852404 — intervention group
Group type: COMPARATOR
Intervention: Control (no BM 15.075)
Number of subjects: 15
Study 31771924 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer sex media campaign (Project iMPPACS)
Number of subjects: 1658
Study 31771924 — intervention group
Group type: COMPARATOR
Intervention: Nonmedia cities (control)
Number of subjects: 1658
Study 30955955 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade stent delivery
Number of subjects: 178
Study 30955955 — intervention group
Group type: COMPARATOR
Intervention: Standard repair
Number of subjects: 178
Study 28549484 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-based CBT combined with health-related serious gaming elements for 6 weeks
Number of subjects: 60
Study 28549484 — intervention group
Group type: COMPARATOR
Intervention: Control condition receiving no intervention
Number of subjects: 60
Study 24950758 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-micron continuous-wave laser treatment
Number of subjects: 142
Study 24950758 — intervention group
Group type: COMPARATOR
Intervention: Conventional transurethral resection of bladder tumor (TURBT)
Number of subjects: 142
Study 23852296 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/day mifepristone for 3 months
Number of subjects: 143